Novel approaches for reducing free light chains in patients with myeloma kidney. - Wikidata - wikimedia - TriplyDB

Novel approaches for reducing free light chains in patients with myeloma kidney.

Novel approaches for reducing free light chains in patients with myeloma kidney.

http://www.wikidata.org/entity/Q37986358

about

Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment.Removal of free light chains in hemodialysis patients without multiple myeloma: a crossover comparison of three different dialyzers Kidney diseases associated with haematological cancers.Managing renal complications in multiple myeloma.Current treatments for renal failure due to multiple myeloma.Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities.A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR).Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.Role of the clinical immunology laboratory in disease monitoring

P2860

Q34448964-5443940C-AFD0-4D7D-8413-AE430701E48A Q36203484-2AD62FBB-C898-4A91-A952-662A70ADF520 Q38513113-150CC5B9-630A-4702-99DF-C8B919629AD4 Q38900024-82A2F5C6-7CAB-4919-9F95-5CD9A2DBA0E7 Q38959138-97AB62F6-413A-4673-9D75-28A0BE34C3F1 Q41078986-1F966886-031A-4B74-AFD1-2397E28FEA7D Q47562792-CEC1CC22-CA5E-45C3-8A2A-19C2FA87037A Q51061553-B68C26C7-24F7-44ED-B7DB-A33CF8AC22F4 Q53173592-FE1DE7B0-B46D-4E74-BB8C-125132391874 Q59102177-037176E3-88B8-4178-80EF-EB2DE8A11853

P2860

Novel approaches for reducing free light chains in patients with myeloma kidney.

http://www.wikidata.org/entity/Q37986358

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Novel approaches for reducing free light chains in patients with myeloma kidney.

@en

Novel approaches for reducing free light chains in patients with myeloma kidney.

@nl

type

label

Novel approaches for reducing free light chains in patients with myeloma kidney.

@en

Novel approaches for reducing free light chains in patients with myeloma kidney.

@nl

prefLabel

Novel approaches for reducing free light chains in patients with myeloma kidney.

@en

Novel approaches for reducing free light chains in patients with myeloma kidney.

@nl

P1433

Q37986358-0033CF08-9263-44E2-A1FC-E889A85C6678

P1476

Q37986358-86D15364-6E5C-4EFC-AA98-816D100230A1

P2093

Q37986358-05242DE7-1756-4EA6-AAD8-F803472E5655

Q37986358-26C6FC47-3BFC-4F37-8A96-8B97C9F4D82C

Q37986358-400C16E6-29EC-49B5-ACC5-2542CA050E30

Q37986358-5B51C0F3-BDF3-4E6C-9C81-EE7B35E37C50

Q37986358-77E826FD-20CC-4353-A089-F55F5E1B6145

Q37986358-A01A0A2B-B2E0-4EE4-BE23-A1D15F8B8C3E

Q37986358-A2DF2590-F499-4367-98AD-BD0F6E9A9985

Q37986358-DE841FD1-C036-495A-8A59-A3ABD84480AB

P2860

Q37986358-01356A77-37C4-4E0A-ADE3-35E1F49F022B

Q37986358-01DC3331-3E72-434E-A712-CEE068D0713B

Q37986358-0805B293-2966-48D3-8747-0F0250C3C99F

Q37986358-08068F0B-BB61-413B-A40C-9E8186085CAD

Q37986358-0AF3F191-E747-4250-9243-768DC9671F5E

Q37986358-13B1FB2C-6E99-4B00-B13C-58E3CB55C4CF

Q37986358-17BB803B-DF54-4FB1-ABBD-D1AD3E75354D

Q37986358-1DBCD4DC-D72F-470D-8D60-B350B7E53CE2

Q37986358-2098E353-5F70-4E15-BEF6-4C8E758C9DCF

Q37986358-2273B7BF-38EA-41D7-A8F9-883850E81375

P2888

Q37986358-8358471F-5554-4D05-A418-D72E595036C7

P304

Q37986358-36F2BD30-317A-4A6D-BA6D-B95FB5E5B2D9

P31

Q37986358-7DBFAE8A-FA39-490F-BA46-C1136C1DD663

P356

Q37986358-54570BBC-CE7F-4C09-85E1-6BF66043A7E3

P407

Q37986358-37FCE228-AC7A-4DEE-AD92-F7C676E3EEB9

P433

Q37986358-5F50B58F-613A-41C4-94D1-809A89FE391A

P478

Q37986358-9C69DF50-19DA-4199-A0CB-1DFD78351F87

P50

Q37986358-665876BA-F40C-4761-A1F9-B477EDFF1044

Q37986358-9734F158-9E89-42C2-9AF3-E21174DD3078

Q37986358-A53C0083-E283-4AE5-8D29-3FED79A68000

Q37986358-FAE309AC-9096-403E-8A56-2FF15DA7F599

P577

Q37986358-70DA4209-5847-4BD8-AE74-1C2AC7441314

P5875

Q37986358-18D0CE49-74C7-417F-B8B5-E9D44542F033

P698

Q37986358-97477E4E-B9BF-4EA2-8E6A-61ACC5F55797

P356

P1433

Nature Reviews Nephrology

P1476

Novel approaches for reducing free light chains in patients with myeloma kidney

@en

P2093

Christopher Winearls

http://www.w3.org/2001/XMLSchema#string

Colin A Hutchison

http://www.w3.org/2001/XMLSchema#string

International Kidney and Monoclonal Gammopathy Research Group

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Fermand

http://www.w3.org/2001/XMLSchema#string

Joan Bladé

http://www.w3.org/2001/XMLSchema#string

Mark Drayson

http://www.w3.org/2001/XMLSchema#string

Robert Kyle

http://www.w3.org/2001/XMLSchema#string

Sonia Pasquali

http://www.w3.org/2001/XMLSchema#string

P2860

Pathobiology of cast nephropathy from human Bence Jones proteins

The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.

Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy.

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

P2888

P304

234-243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRNEPH.2012.14

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Efstathios Kastritis

P577

2012-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221846795

http://www.w3.org/2001/XMLSchema#string

P698

22349488

http://www.w3.org/2001/XMLSchema#string